notificationsアラート設定
~
検索条件をクリア

アブストラクト

Title 急性増悪の診断と治療
Subtitle 特集 間質性肺炎診療の今・未来 I 特発性間質性肺炎の診療
Authors 近藤康博*, 横山俊樹*,**
Authors (kana)
Organization *公立陶生病院呼吸器・アレルギー疾患内科, **公立陶生病院救急部集中治療室
Journal Pharma Medica
Volume 38
Number 3
Page 27-31
Year/Month 2020 / 3
Article 報告
Publisher メディカルレビュー社
Abstract 「はじめに」特発性間質性肺炎(idiopathic interstitial pneumonias:IIPs)には複数の疾患が含まれ, 慢性進行性経過を呈する疾患としては, 特発性肺線維症(idiopathic pulmonary fibrosis:IPF)や非特異性間質性肺炎(nonspecific interstitial pneumonia:NSIP)が代表的であるが, その他にも上葉優位型肺線維症や分類不能のIIPsなどがある. これら慢性線維化性間質性肺炎は, 通常, 緩徐な経過で進行するが, ときに「急性増悪」という急速な呼吸不全の増悪を呈する. 本稿では, この間質性肺炎の急性増悪につき概説する. 「I. 疾患概念」間質性肺炎の急性増悪は, 1993年にIPF症例においてわが国より初めて報告された概念である. その後, IPF以外の間質性肺炎においても急性増悪を起こすことが報告されている.
Practice 薬学
Keywords 特発性肺線維症(IPF), 特発性間質性肺炎(IIPs), 急性憎悪, 非侵襲的陽圧換気(NPPV), 高流量経鼻酸素療法(HFNC-OT)
  • 全文ダウンロード： 従量制、基本料金制の方共に913円(税込) です。
download全文ダウンロード(7.11MB)

参考文献

  • 1) Travis WD, Costabel U, Hansell DM, et al;ATS/ERS Committee on Idiopathic Interstitial Pneumonias. An official American Thoracic Society/European Respiratory Society statement:Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188:733-48.
    pubmed
  • 2) Suzuki A, Kondoh Y, Brown KK, et al. Acute exacerbations of fibrotic interstitial lung diseases. Respirology. 2019 Aug 19. doi:10.1111/resp.13682. [Epub ahead of print]
  • 3) Kondoh Y, Taniguchi H, Kawabata Y, et al. Acute exacerbation in idiopathic pulmonary fibrosis. Analysis of clinical and pathologic findings in three cases. Chest. 1993;103:1808-12.
    pubmed
  • 4) Mallick S. Outcome of patients with idiopathic pulmonary fibrosis (IPF) ventilated in intensive care unit. Respir Med. 2008;102:1355-9.
    pubmed
  • 5) Kondoh Y, Cottin V, Brown KK. Recent lessons learned in the management of acute exacerbation of idiopathic pulmonary fibrosis. Eur Respir Rev. 2017;26:170050.
    pubmed
残りの18件を表示する
  • 6) Nagata K, Tomii K, Otsuka K, et al. Serum procalcitonin is a valuable diagnostic marker in acute exacerbation of interstitlal pneumonia. Respirology. 2013;18:439-46.
    pubmed
  • 7) Akira M, Kozuka T, Yamamoto S, et al. Computed tomography findings in acute exacerbation of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2008;178:372-8.
    pubmed
  • 8) Fujimoto K, Taniguchi H, Johkoh T, et al. Acute exacerbation of idiopathic pulmonary fibrosis:high-resolution CT scores predict mortality. Eur Radiol. 2012;22:83-92.
    pubmed
  • 9) 日本呼吸器学会, びまん性肺疾患診断・治療ガイドライン作成委員会 編. 特発性間質性肺炎診断と治療の手引き (改訂第3版). 東京:南江堂;2016.
  • 10) Collard HR, Ryerson CJ, Corte TJ, et al. Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. Am J Respir Crit Care Med. 2016;194:265-75.
  • 11) 厚生労働科学研究費補助金難治性疾患政策研究事業「びまん性肺疾患に関する調査研究」班, 特発性肺線維症の治療ガイドライン作成委員会 編. 特発性肺線維症の治療ガイドライン2017. 東京:南江堂;2017.
  • 12) Isshiki T, Sakamoto S, Kinoshita A, et al. Recombinant human soluble thrombomodulin treatment for acute exacerbation of idiopathic pulmonary fibrosis:a retrospective study. Respiration. 2015;89:201-7.
    pubmed
  • 13) Kataoka K, Taniguchi H, Kondoh Y, et al. Recombinant Human Thrombomodulin in Acute Exacerbation of Idiopathic Pulmonary Fibrosis. Chest. 2015;148:436-43.
    pubmed
  • 14) Tsushima K, Yamaguchi K, Kono Y, et al. Thrombomodulin for acute exacerbations of idiopathic pulmonary fibrosis:a proof of concept study. Pulm Pharmacol Ther. 2014;29:233-40.
    pubmed
  • 15) Hilbert G, Gruson D, Vargas F, et al. Noninvasive ventilation in immunosuppressed patients with pulmonary infiltrates, fever, and acute respiratory failure. N Engl J Med. 2001;344:481-7.
    pubmed
  • 16) Tomii K, Tachikawa R, Chin K, et al. Role of non-invasive ventilation in managing life-threatening acute exacerbation of interstitial pneumonia. Intern Med, 2010;49:1341-7.
    pubmed
  • 17) Yokoyama T, Kondoh Y, Taniguchi H, et al. Noninvasive ventilation in acute exacerbation of idiopathic pulmonary fibrosis. Intern Med. 2010;49:1509-14.
    pubmed
  • 18) Yokoyama T, Tsushima K, Yamamoto H, et al. Potential benefits of early continuous positive pressure ventilation in patients with rapidly progressive interstitial pneumonia. Respirology. 2012;17:315-21.
    pubmed
  • 19) Taniguchi H, Kondoh Y. Acute and subacute idiopathic interstitial pneumonias. Respirology. 2016;21:810-20.
    pubmed
  • 20) Coudroy R, Jamet A, Petua P, et al. High-flow nasal cannula oxygen therapy versus noninvasive ventilation in immunocompromised patients with acute respiratory failure:an observational cohort study. Ann Intensive Care. 2016;6:45.
    pubmed
  • 21) Frat JP, Ragot S, Girault C, et al. Effect of non-invasive oxygenation strategies in immunocompromised patients with severe acute respiratory failure:a post-hoc analysis of a randomised trial. Lancet Respir Med. 2016;4:646-52.
    pubmed
  • 22) Azoulay E, Lemiale V, Mokart D, et al. Effect of High-Flow Nasal Oxygen vs Standard Oxygen on 28-Day Mortality in Immunocompromised Patients With Acute Respiratory Failure:The HIGH Randomized Clinical Trial. JAMA. 2018;320:2099-107.
    pubmed
  • 23) Koyauchi T, Hasegawa H, Kanata K, et al. Efficacy and Tolerability of High-Flow Nasal Cannula Oxygen Therapy for Hypoxemic Respiratory Failure in Patients with Interstitial Lung Disease with Do-Not-Intubate Orders:A Retrospective Single-Center Study. Respiration. 2018;96:323-9.
はじめての方へ
個人／法人会員登録のご案内